146 related articles for article (PubMed ID: 14980746)
21. The analysis of very small samples of repeated measurements I: an adjusted sandwich estimator.
Skene SS; Kenward MG
Stat Med; 2010 Nov; 29(27):2825-37. PubMed ID: 20839367
[TBL] [Abstract][Full Text] [Related]
22. A unifying approach for surrogate marker validation based on Prentice's criteria.
Alonso A; Molenberghs G; Geys H; Buyse M; Vangeneugden T
Stat Med; 2006 Jan; 25(2):205-21. PubMed ID: 16220497
[TBL] [Abstract][Full Text] [Related]
23. Semiparametric models for missing covariate and response data in regression models.
Chen Q; Ibrahim JG
Biometrics; 2006 Mar; 62(1):177-84. PubMed ID: 16542244
[TBL] [Abstract][Full Text] [Related]
24. Covariate adjustment in clinical trials with non-ignorable missing data and non-compliance.
Levy DE; O'Malley AJ; Normand SL
Stat Med; 2004 Aug; 23(15):2319-39. PubMed ID: 15273951
[TBL] [Abstract][Full Text] [Related]
25. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
Sullivan LM; D'Agostino RB
Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
[TBL] [Abstract][Full Text] [Related]
26. Varying cluster sizes in trials with clusters in one treatment arm: sample size adjustments when testing treatment effects with linear mixed models.
Candel MJ; Van Breukelen GJ
Stat Med; 2009 Aug; 28(18):2307-24. PubMed ID: 19472169
[TBL] [Abstract][Full Text] [Related]
27. Inference of nested variance components in a longitudinal myopia intervention trial.
Hsiao CK; Tsai MY; Chen HM
Stat Med; 2005 Nov; 24(21):3251-67. PubMed ID: 16206249
[TBL] [Abstract][Full Text] [Related]
28. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
[TBL] [Abstract][Full Text] [Related]
29. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
30. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
31. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
32. Adjusting sample size for anticipated dropouts in clinical trials.
Overall JE; Shobaki G; Shivakumar C; Steele J
Psychopharmacol Bull; 1998; 34(1):25-33. PubMed ID: 9564195
[TBL] [Abstract][Full Text] [Related]
33. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Arman S; Sadramely MR; Nadi M; Koleini N
Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
[TBL] [Abstract][Full Text] [Related]
35. Power calculations for generalized linear models in observational longitudinal studies: a simulation approach in SAS.
Gastañaga VM; McLaren CE; Delfino RJ
Comput Methods Programs Biomed; 2006 Oct; 84(1):27-33. PubMed ID: 16982112
[TBL] [Abstract][Full Text] [Related]
36. Issues in use of SAS PROC.MIXED to test the significance of treatment effects in controlled clinical trials.
Ahn C; Tonidandel S; Overall JE
J Biopharm Stat; 2000 May; 10(2):265-86. PubMed ID: 10803729
[TBL] [Abstract][Full Text] [Related]
37. A mixed-effects model for categorical data.
Beitler PJ; Landis JR
Biometrics; 1985 Dec; 41(4):991-1000. PubMed ID: 3830263
[TBL] [Abstract][Full Text] [Related]
38. Generalizability in nongaussian longitudinal clinical trial data based on generalized linear mixed models.
Vangeneugden T; Molenberghs G; Laenen A; Alonso A; Geys H
J Biopharm Stat; 2008; 18(4):691-712. PubMed ID: 18607802
[TBL] [Abstract][Full Text] [Related]
39. Mixed-effect models to assess consistency and reliability across multiple evaluations.
Kao TC; Sparling Y; Rochon J
J Biopharm Stat; 2003 Aug; 13(3):539-48. PubMed ID: 12921400
[TBL] [Abstract][Full Text] [Related]
40. How many repeated measurements are useful?
Overall JE
J Clin Psychol; 1996 May; 52(3):243-52. PubMed ID: 8835686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
